ALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) have been assigned a consensus recommendation of “Moderate Buy” from the six analysts that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $2.50.

ALXO has been the topic of several research analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ALX Oncology in a research note on Wednesday, January 21st. Jefferies Financial Group started coverage on shares of ALX Oncology in a research report on Thursday, November 13th. They set a “buy” rating and a $4.00 price target on the stock. Piper Sandler increased their price objective on shares of ALX Oncology from $3.00 to $4.00 and gave the stock an “overweight” rating in a research report on Thursday, February 5th. Finally, Wall Street Zen raised shares of ALX Oncology from a “sell” rating to a “hold” rating in a research note on Monday, December 22nd.

ALX Oncology Price Performance

ALXO stock opened at $2.45 on Friday. The company has a market cap of $132.84 million, a PE ratio of -1.21 and a beta of 0.51. The company has a current ratio of 2.40, a quick ratio of 2.40 and a debt-to-equity ratio of 0.13. The stock has a 50-day moving average price of $1.61 and a two-hundred day moving average price of $1.44. ALX Oncology has a 12-month low of $0.40 and a 12-month high of $2.66.

Insider Buying and Selling

In related news, Director Corey S. Goodman acquired 3,184,713 shares of the business’s stock in a transaction on Monday, February 2nd. The shares were bought at an average cost of $1.57 per share, with a total value of $4,999,999.41. Following the completion of the transaction, the director directly owned 8,453,038 shares of the company’s stock, valued at $13,271,269.66. This trade represents a 60.45% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 21.00% of the stock is owned by company insiders.

Institutional Investors Weigh In On ALX Oncology

A number of large investors have recently modified their holdings of the stock. Ameriprise Financial Inc. purchased a new stake in shares of ALX Oncology during the 3rd quarter valued at about $1,195,000. Renaissance Technologies LLC grew its position in ALX Oncology by 157.2% in the fourth quarter. Renaissance Technologies LLC now owns 423,099 shares of the company’s stock valued at $478,000 after acquiring an additional 258,600 shares in the last quarter. Jane Street Group LLC purchased a new stake in shares of ALX Oncology during the second quarter valued at approximately $84,000. Acadian Asset Management LLC raised its stake in shares of ALX Oncology by 16.8% during the first quarter. Acadian Asset Management LLC now owns 1,296,331 shares of the company’s stock valued at $806,000 after purchasing an additional 186,883 shares during the period. Finally, Two Sigma Investments LP lifted its position in shares of ALX Oncology by 26.9% during the third quarter. Two Sigma Investments LP now owns 606,671 shares of the company’s stock worth $1,110,000 after purchasing an additional 128,737 shares in the last quarter. Institutional investors and hedge funds own 97.97% of the company’s stock.

ALX Oncology Company Profile

ALX Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Redwood City, California, focused on developing next-generation immuno-oncology therapies. The company’s mission is to harness and amplify both innate and adaptive immune responses to improve outcomes for patients with a range of solid tumors and hematologic malignancies.

The lead candidate in ALX Oncology’s pipeline is evorpacept (ALX148), a high-affinity CD47-blocking Fc-silenced fusion protein designed to enhance macrophage-mediated phagocytosis of cancer cells when combined with standard therapeutic antibodies or immune checkpoint inhibitors.